Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus
Lupus Erythematosus, Systemic
Severity of Illness Index
The SRI and its modified versions based on meaningful changes in jSLE have high specificity but at most modest sensitivity for capturing jSLE improvement. When used as an endpoint of clinical trials in jSLE, the SRI will provide a conservative estimate regarding the efficacy of the therapeutic agent under investigation.